Back to Search
Start Over
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
- Source :
- Investigational New Drugs; Apr2013, Vol. 31 Issue 2, p399-408, 10p
- Publication Year :
- 2013
- Subjects :
- PHARMACOKINETICS
ANTINEOPLASTIC agents
BIOMARKERS
BIOPSY
CELL receptors
CLINICAL trials
DOSE-response relationship in biochemistry
DRUGS
EPIDERMAL growth factor
IMMUNOHISTOCHEMISTRY
ONCOGENES
PHARMACEUTICAL arithmetic
PHOSPHOTRANSFERASES
RESEARCH funding
T-test (Statistics)
TUMORS
DATA analysis software
DESCRIPTIVE statistics
CHEMICAL inhibitors
PHARMACODYNAMICS
Subjects
Details
- Language :
- English
- ISSN :
- 01676997
- Volume :
- 31
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Investigational New Drugs
- Publication Type :
- Academic Journal
- Accession number :
- 85896616
- Full Text :
- https://doi.org/10.1007/s10637-012-9890-y